Hot Stock

["W"]

SOUTH SAN FRANCISCO, Calif., May 18, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT(TM) in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC) and non-small cell lung cancer (NSCLC) will be presented at the upcoming American Society of Clinical Oncology annual meeting in Chicago, Illinois on June 3-7, 2011.
OXiGENE also announced that the FACT oral presentation was selected to be included in the Best of ASCO(R) program, which will be held shortly after the ASCO Annual Meeting. The Best of ASCO is an educational initiative that condenses highlights from ASCO's Annual Meeting into a two-day program and is intended to increase global access to cutting-edge science. Abstracts were selected according to specific criteria and reflect research that is relevant and significant in oncology today. In addition to two domestic Best of ASCO meetings in Miami and Seattle, there will also be approximately eighteen International Best of ASCO Meetings and various ASCO-licensed packages.
FACT (Fosbretabulin in Anaplastic Cancer of the Thyroid) Presentation Details:

Oral Presentation Title: A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial

Presenter: Julie A Sosa, MD, Yale University School of Medicine

Session Title: Head and Neck Cancer

Date: Monday, June 6, 2011

Session Time: 3:00PM - 6:00PM CDT

Location: McCormick Place S406